Abstract:Background: Currently, no satisfactory biomarkers are available to screen for lung cancer. Surface-Enhanced Laser Desorption/ionization Time-of- Flight Mass Spectrometry ProteinChip system (SELDI-TOF-MS) is one of the currently used techniques to identify biomarkers for cancers. The aim of this study is to explore the application of serum SELDI proteomic patterns to distinguish lung cancer patients from healthy individuals.Methods: A total of 208 serum samples, including 158 lung cancer patients and 50 healthy individuals, were randomly divided into a training set (including 11 sera from patients with stages I/II lung cancer, 63 from patients with stages III/IV lung cancer and 20 from healthy controls) and a blinded test set (including 43 sera from patients with stages I/II lung cancer, 41 from patients with stages III/IV lung cancer and 30 from healthy controls). All samples were analyzed by SELDI technology. The spectra were generated on weak cation exchange (WCX2) chips, and protein peaks clustering and classification analyses were made using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively. We additionally determined Cyfra21-1 and NSE in the 208 serum samples included in this study using an electrochemiluminescent immunoassay.Results: Five protein peaks at 11493, 6429, 8245, 5335 and 2538 Da were automatically chosen as a biomarker pattern in the training set. When the SELDI marker pattern was tested with the blinded test set, it yielded a sensitivity of 86.9%, a specificity of 80.0% and a positive predictive value of 92.4%. The sensitivities provided by Cyfra21-1 and NSE used individually or in combination were significantly lower than that of the SELDI marker pattern (P < 0.005 or 0.05, respectively). Based on the results of the test set, we found that the SELDI marker pattern showed a sensitivity of 91.4% in the detection of non-small cell lung cancers (NSCLC), which was significantly higher than that in the detection of small cell lung cancers (P < 0.05); The pattern also had a sensitivity of 79.1% in the detection of lung cancers in stages I/II.Conclusion: These results suggest that serum SELDI protein profiling can distinguish lung cancer patients, especially NSCLC patients, from normal subjects with relatively high sensitivity and specificity, and the SELDI- TOF- MS is a potential tool for the screening of lung cancer.

Tree Analysis of Mass Spectral Urine Profiles Discriminates Transitional Cell Carcinoma of the Bladder from Noncancer Patient

Tree Analysis Pattern of Mass Spectral Urine Profiles in Differential Diagnosis of Bladder Transitional Cell Carcinoma

Using Tree Analysis Pattern and SELDI-TOF-MS to Discriminate Transitional Cell Carcinoma of the Bladder Cancer from Noncancer Patients

Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer

Microfluidic Assaying of Circulating Tumor Cells and its Correlation with Muscle Invasiveness and Tumor Grade of Urothelial Bladder Cancer

SELDI-TOF-MS ProteinChip Technology for Screening of Urine Markers of Bladder Carcinoma

Bladder Cancer Determination Via Two Urinary Metabolites: A Biomarker Pattern Approach

Establishing a model of classification tree for stage I colorectal cancer using surface-enhanced laser desorption ionization time-of-flight mass spectrometry

Diagnosis of Gastric Cancer Using Decision Tree Classification of Mass Spectral Data

[Proteomic analysis in combination with CT diagnosis to distinguish renal cell carcinoma from renal benign masses]

Urine metabolomics and proteomics for bladder cancer prediction by LC/MS based strategy

UPLC-Q-TOF/MS-based Urine Metabolomics for the Diagnosis and Staging of Bladder Cancer

Integration of the cancer cell secretome and transcriptome reveals potential noninvasive diagnostic markers for bladder cancer

Urine-based SERS and multivariate statistical analysis for identification of non-muscle-invasive bladder cancer and muscle-invasive bladder cancer

Exploration of potential biomarkers for early bladder cancer based on urine proteomics

Data from Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification

Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer

Study of Distinct Protein Profiles for Early Diagnosis of NSCLC Using LCM and SELDI-TOF-MS

LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery.

Profiling of Urine Carbonyl Metabolic Fingerprints in Bladder Cancer Based on Ambient Ionization Mass Spectrometry

Application of Serum Seldi Proteomic Patterns in Diagnosis of Lung Cancer